AR126820A1 - Anticuerpos - Google Patents
AnticuerposInfo
- Publication number
- AR126820A1 AR126820A1 ARP220102228A ARP220102228A AR126820A1 AR 126820 A1 AR126820 A1 AR 126820A1 AR P220102228 A ARP220102228 A AR P220102228A AR P220102228 A ARP220102228 A AR P220102228A AR 126820 A1 AR126820 A1 AR 126820A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- seq
- cdr
- hla
- host cell
- Prior art date
Links
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 abstract 6
- 108010024164 HLA-G Antigens Proteins 0.000 abstract 6
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 239000013604 expression vector Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000006471 Fucosyltransferases Human genes 0.000 abstract 1
- 108010019236 Fucosyltransferases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000013599 cloning vector Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos dirigidos contra HLA-G y formulaciones que los comprenden. La invención se refiere, además, al uso de los anticuerpos HLA-G y formulaciones en tratamientos, en especial en el tratamiento de tumores sólidos. Reivindicación 1: Un anticuerpo que se une específicamente a HLA-G, en donde el anticuerpo comprende: a. una región variable de cadena ligera que comprende: i. una CDR-L1 que comprende el SEQ ID Nº 1; ii. una CDR-L2 que comprende el SEQ ID Nº 2 y iii. una CDR-L3 que comprende el SEQ ID Nº 3, y b. una región variable de cadena pesada que comprende: i. una CDR-H1 que comprende el SEQ ID Nº 4; ii. una CDR-H2 que comprende el SEQ ID Nº 5 y iii. una CDR-H3 que comprende el SEQ ID Nº 6. Reivindicación 22: Un anticuerpo que compite de forma cruzada con el anticuerpo de la reivindicación 1 para unirse a HLA-G o se une a un epítopo de HLA-G que comprende V194, F195, Y197, E198, Q224, Q226, D227, V248, V249, P250 e Y257 de HLA-G (SEQ ID Nº 107). Reivindicación 23: Un polinucleótido aislado que codifica el anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 22. Reivindicación 26: Un vector de clonación o de expresión que comprende uno o más polinucleótidos de acuerdo con una cualquiera de las reivindicaciones 23 a 25. Reivindicación 27: Una célula hospedante que comprende uno o más polinucleótidos de acuerdo con una cualquiera de las reivindicaciones 23 a 25 o uno o más vectores de expresión de acuerdo con la reivindicación 26. Reivindicación 28: Una célula hospedante que comprende uno o más polinucleótidos de acuerdo con una cualquiera de las reivindicaciones 23 a 25 o uno o más vectores de expresión de acuerdo con la reivindicación 26, en donde la célula hospedante fue modificada genéticamente para disminuir o suprimir la función de la a1,6 fucosiltransferasa. Reivindicación 29: Un proceso para la producción de un anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 22, que comprende cultivar la célula hospedante de acuerdo con la reivindicación 27 o 28 en condiciones adecuadas para producir el anticuerpo y aislar el anticuerpo. Reivindicación 30: Un proceso para la producción de una composición farmacéutica que comprende el anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 22, que comprende las etapas del proceso como se define en la reivindicación 29 y que comprende, además, formular el anticuerpo en una composición farmacéutica. Reivindicación 31: Una composición farmacéutica que comprende el anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 22 y uno o más vehículos, excipientes o diluyentes farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2111905.2A GB202111905D0 (en) | 2021-08-19 | 2021-08-19 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126820A1 true AR126820A1 (es) | 2023-11-15 |
Family
ID=77913991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102228A AR126820A1 (es) | 2021-08-19 | 2022-08-18 | Anticuerpos |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4388007A1 (es) |
| KR (1) | KR20240046577A (es) |
| CN (1) | CN118369341A (es) |
| AR (1) | AR126820A1 (es) |
| AU (1) | AU2022330347A1 (es) |
| BR (1) | BR112024001989A2 (es) |
| CA (1) | CA3227160A1 (es) |
| CO (1) | CO2024001711A2 (es) |
| GB (1) | GB202111905D0 (es) |
| IL (1) | IL310245A (es) |
| TW (1) | TW202315889A (es) |
| WO (1) | WO2023021187A1 (es) |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| DK1049787T3 (da) | 1998-01-23 | 2005-04-04 | Vlaams Interuniv Inst Biotech | Antistofderivater med flere anvendelsesmuligheder |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| WO2003102157A2 (en) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ATE528648T1 (de) | 2002-12-03 | 2011-10-15 | Ucb Pharma Sa | Verfahren zum nachweis antikörper-herstellender zellen |
| EP1572744B1 (en) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| GB0513852D0 (en) | 2005-07-06 | 2005-08-10 | Celltech R&D Ltd | Biological products |
| WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AU2007227292B2 (en) | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| DK2334705T3 (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス，インコーポレイテッド | Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
| US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201411420D0 (en) | 2014-06-26 | 2014-08-13 | Ucb Biopharma Sprl | Antibody constructs |
| JP7034950B2 (ja) * | 2016-06-03 | 2022-03-14 | アンヴェクティ | 抗ｈｌａ－ｇ特異的抗体 |
| TW201829463A (zh) * | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| EP3434688A1 (en) * | 2017-07-24 | 2019-01-30 | Commissariat à l'Energie Atomique et aux Energies Alternatives | Hla-g transcripts and isoforms and their uses |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| EA202190609A1 (ru) | 2018-09-27 | 2021-08-17 | Тизона Терапьютикс | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g |
-
2021
- 2021-08-19 GB GBGB2111905.2A patent/GB202111905D0/en not_active Ceased
-
2022
- 2022-08-18 AR ARP220102228A patent/AR126820A1/es unknown
- 2022-08-19 IL IL310245A patent/IL310245A/en unknown
- 2022-08-19 TW TW111131251A patent/TW202315889A/zh unknown
- 2022-08-19 CA CA3227160A patent/CA3227160A1/en active Pending
- 2022-08-19 EP EP22769886.7A patent/EP4388007A1/en active Pending
- 2022-08-19 WO PCT/EP2022/073195 patent/WO2023021187A1/en active Application Filing
- 2022-08-19 AU AU2022330347A patent/AU2022330347A1/en active Pending
- 2022-08-19 CN CN202280063210.8A patent/CN118369341A/zh active Pending
- 2022-08-19 BR BR112024001989A patent/BR112024001989A2/pt unknown
- 2022-08-19 KR KR1020247009075A patent/KR20240046577A/ko unknown
-
2024
- 2024-02-19 CO CONC2024/0001711A patent/CO2024001711A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227160A1 (en) | 2023-02-23 |
| CO2024001711A2 (es) | 2024-03-07 |
| WO2023021187A1 (en) | 2023-02-23 |
| BR112024001989A2 (pt) | 2024-04-30 |
| KR20240046577A (ko) | 2024-04-09 |
| GB202111905D0 (en) | 2021-10-06 |
| IL310245A (en) | 2024-03-01 |
| AU2022330347A1 (en) | 2024-02-01 |
| CN118369341A (zh) | 2024-07-19 |
| TW202315889A (zh) | 2023-04-16 |
| EP4388007A1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
| AR111203A1 (es) | Inmunoconjugados | |
| PE20040519A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| PE20240814A1 (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso | |
| AR109535A2 (es) | Anticuerpos inhibidores de la dimerización del c-met y usos de los mismos | |
| AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
| JP2017534256A5 (es) | ||
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| JP2010022372A5 (es) | ||
| AR088579A1 (es) | Formulaciones de anticuerpos | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
| PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| AR079217A1 (es) | Composiciones y metodos para el diagnostico y el tratamiento de tumores | |
| PE20212324A1 (es) | Anticuerpos que reconocen tau | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| MX2022006132A (es) | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso |